ATORVASTATIN AS AN ADJUNCTIVE THERAPY IN PATIENTS OF SCHIZOPHRENIA AND ITS RELATION TO C REACTIVE PROTEIN:A RANDOMISED PLACEBO CONTROLLED OPEN LABEL STUDY

CENTRAL INSTITUTE OF PSYCHIATRY0 个研究点目标入组 0 人开始时间: 待定最近更新: 2021年11月24日

试验速览

暂无简介。

•a) Patients admitted in the Institute and satisfying the ICD 10-DCR[1993] criteria for schizophrenia[ with illness duration more than or equal to 2 years] b) Age group of 18-50 years of both sexes c) Drug naive patients or drug free for minimum 2 weeks on oral antipsychotics & 4 weeks for depot preparation d) Those who give informed consent for participating in the study.

•a) Any other major co-morbid psychiatric diagnosis and substance dependence excluding nicotine & caffeine. b) Significant medical or neurological illness including severe cardiovascular, hepatic, renal,[serum creatinine > 1.5 mg/dl], anaemia [Haemoglobin < 11 mg/dl], history of severe head injury or myopathy or untreated thyroid disease. c) Pregnancy
•8 | P a g e
•d) BMI >30 kg/m2 e) Not willing to give written informed consent f) Current treatment with Insulin, medications known to affect glucose tolerance anti-inflammatory drugs including NSAIDS, thiazide diuretics, agents that induce weight loss]. g) Current treatment with drugs that induce or inhibit metabolism of statins [Azole antifungals, Macrolide antibiotics, Carbamazepine, anti-retroviral protease inhibitors] h) Known hypersensitivity to Tab. Atorvastatin or any of its components i) Any current systemic infection/ inflammation

发起方